|
1
|
Friedman DS, O'Colmain BJ, Muñoz B, Tomany
SC, McCarty C, de Jong PT, Nemesure B, Mitchell P and Kempen J: Eye
Diseases Prevalence Research Group. Prevalence of age-related
macular degeneration in the United States. Arch Ophthalmol.
122:564–572. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wong WL, Su X, Li X, Cheung CMG, Klein R,
Cheng CY and Wong TY: Global prevalence of age-related macular
degeneration and disease burden projection for 2020 and 2040: A
systematic review and meta-analysis. Lancet Glob Health.
2:e106–e116. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Klein R and Klein BE: The prevalence of
age-related eye diseases and visual impairment in aging: Current
estimates. Invest Ophthalmol Vis Sci. 54:ORSF5–ORSF13.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brody BL, Gamst AC, Williams RA, Smith AR,
Lau PW, Dolnak D, Rapaport MH, Kaplan RM and Brown SI: Depression,
visual acuity, comorbidity, and disability associated with
age-related macular degeneration. Ophthalmology. 108:1893–1901.
2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gusar I, Čanović S, Ljubičić M, Šare S,
Perić S, Caktaš IL, Kovačević P, Paštar Z and Konjevoda S:
Religiousness, anxiety and depression in patients with glaucoma,
age-related macular degeneration and diabetic retinopathy.
Psychiatr Danub. 33 (Suppl 4):S965–S973. 2021.PubMed/NCBI
|
|
6
|
Macnamara A, Chen C, Schinazi VR,
Saredakis D and Loetscher T: Simulating macular degeneration to
investigate activities of daily living: A systematic review. Front
Neurosci. 15(663062)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mitchell P, Liew G, Gopinath B and Wong
TY: Age-related macular degeneration. Lancet. 392:1147–1159.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ricci F, Bandello F, Navarra P, Staurenghi
G, Stumpp M and Zarbin M: Neovascular age-related macular
degeneration: Therapeutic management and new-upcoming approaches.
Int J Mol Sci. 21(8242)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Park YG, Park YS and Kim IB: Complement
system and potential therapeutics in age-related macular
degeneration. Int J Mol Sci. 22(6851)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lavine JA, Sang Y, Wang S, Ip MS and
Sheibani N: Attenuation of choroidal neovascularization by
β(2)-adrenoreceptor antagonism. JAMA Ophthalmol. 131:376–382.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cho YK, Shin EY, Uehara H and Ambati B:
The effect of 0.5% timolol maleate on Corneal(Lymph)Angiogenesis in
a murine suture model. J Ocul Pharmacol Ther. 34:403–409.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Traband A, Shaffer JA and VanderBeek BL:
Systemic beta-blockers in neovascular age-related macular
degeneration. Retina. 37:41–46. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kolomeyer AM, Maguire MG, Pan W and
VanderBeek BL: Systemic beta-blockers and risk of progression to
neovascular age-related macular degeneration. Retina. 39:918–925.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Montero JA, Ruiz-Moreno JM, Sanchis-Merino
E and Perez-Martin S: Systemic beta-blockers may reduce the need
for repeated intravitreal injections in patients with wet
age-related macular degeneration treated by bevacizumab. Retina.
33:508–512. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Thomas AS, Redd T and Hwang T: Effect of
systemic beta-blockers, ace inhibitors, and angiotensin receptor
blockers on development of choroidal neovascularization in patients
with age-related macular degeneration. Retina. 35:1964–1968.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Song D, Hua P, VanderBeek BL, Dunaief JL,
Grunwald JE, Daniel E, Maguire MG, Martin DF and Ying GS: CATT
Research Group. Systemic medication use and the incidence and
growth of geographic atrophy in the comparison of age-related
macular degeneration treatments trials. Retina. 41:1455–1462.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Klein R, Myers CE and Klein BEK:
Vasodilators, blood pressure-lowering medications, and age-related
macular degeneration: The beaver dam eye study. Ophthalmology.
121:1604–1611. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Davis A, Cohen SM, Pautler SE,
Billiris-Findlay K and Eichenbaum DA: Beta blocker use and
age-related macular degeneration. Acta Ophthalmol. 90:e162–e163.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yeung L, Huang TS, Lin YH, Hsu KH,
Chien-Chieh Huang J and Sun CC: β-blockers and neovascular
age-related macular degeneration. Ophthalmology. 124:409–411.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ogrodowczyk M, Dettlaff K and Jelinska A:
Beta-blockers: Current state of knowledge and perspectives. Mini
Rev Med Chem. 16:40–54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ristori C, Filippi L, Dal Monte M, Martini
D, Cammalleri M, Fortunato P, la Marca G, Fiorini P and Bagnoli P:
Role of the adrenergic system in a mouse model of oxygen-induced
retinopathy: Antiangiogenic effects of beta-adrenoreceptor
blockade. Invest Ophthalmol Vis Sci. 52:155–170. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW
and Kuan P: Carvedilol modulates the expression of
hypoxia-inducible factor-1alpha and vascular endothelial growth
factor in a rat model of volume-overload heart failure. J Card
Fail. 11:152–159. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dal Monte M, Filippi L and Bagnoli P:
Beta3-adrenergic receptors modulate vascular endothelial growth
factor release in response to hypoxia through the nitric oxide
pathway in mouse retinal explants. Naunyn Schmiedebergs Arch
Pharmacol. 386:269–278. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cheon EW, Park CH, Kang SS, Cho GJ, Yoo
JM, Song JK and Choi WS: Nitric oxide synthase expression in the
transient ischemic rat retina: neuroprotection of betaxolol.
Neurosci Lett. 330:265–269. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hirooka K, Kelly ME, Baldridge WH and
Barnes S: Suppressive actions of betaxolol on ionic currents in
retinal ganglion cells may explain its neuroprotective effects. Exp
Eye Res. 70:611–621. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chidlow G, Melena J and Osborne NN:
Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx
into cortical synaptosomes by direct interaction with Na(+)
channels: Comparison with other beta-adrenoceptor antagonists. Br J
Pharmacol. 130:759–766. 2000.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zając-Pytrus HM, Pilecka A, Turno-Kręcicka
A, Adamiec-Mroczek J and Misiuk-Hojło M: The dry form of
age-related macular degeneration (AMD): The current concepts of
pathogenesis and prospects for treatment. Adv Clin Exp Med.
24:1099–1104. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ammar MJ, Hsu J, Chiang A, Ho AC and
Regillo CD: Age-related macular degeneration therapy: A review.
Curr Opin Ophthalmol. 31:215–221. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Smith CP, Sharma S and Steinle JJ:
Age-related changes in sympathetic neurotransmission in rat retina
and choroid. Exp Eye Res. 84:75–81. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Casini G, Dal Monte M, Fornaciari I,
Filippi L and Bagnoli P: The β-adrenergic system as a possible new
target for pharmacologic treatment of neovascular retinal diseases.
Prog Retin Eye Res. 42:103–129. 2014.PubMed/NCBI View Article : Google Scholar
|
